Drugs / rhHNS
rhHNS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01299727 | Mar 2011 → Apr 2019 | mucopolysaccharidosis type 3A | Shire | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02060526 Comparator | Feb 2014 → Jun 2016 | mucopolysaccharidosis type 3A | Shire | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhHNS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02060526 ↗ |
| Known as | Recombinant human heparan N-sulfatase | “Recombinant human heparan N-sulfatase [rhHNS]” NCT02060526 ↗ |
| Known as | recombinant human HNS | “We report on the efficacy, pharmacokinetics, safety, and tolerability of intrathecal (IT) administration of recombinant human HNS (rhHNS) from a phase IIb randomized open-label trial.” PMID 30528227 ↗ Oct 2018 |
| Modality | Protein / enzyme biologic | “Shire Human Genetic Therapies (Shire HGT) is developing a sulfamidase enzyme replacement therapy (ERT)rhHNS for patients with MPS IIIA.” NCT01299727 ↗ |
| Route | Intrathecal | “rhHNS was administered via an intrathecal drug delivery device (IDDD).” PMID 34600820 ↗ Sep 2021 |